D. Caronia

发表

Standard versus continuous administration of capecitabine in metastatic breast cancer (GEICAM/2009-05): a randomized, noninferiority phase II trial with a pharmacogenetic analysis.

A. González-Neira, G. Pita, A. Lluch, 2015, The oncologist.

A Polymorphism in the Cytidine Deaminase Promoter Predicts Severe Capecitabine-Induced Hand-Foot Syndrome

J. Benítez, A. González-Neira, G. Pita, 2011, Clinical Cancer Research.

Severe Capecitabine-Induced Hand-Foot Syndrome Promoter Predicts Cytidine Deaminase

J. Benítez, G. Pita, M. Alonso, 2011 .

Effect of ABCB1 and ABCC3 Polymorphisms on Osteosarcoma Survival after Chemotherapy: A Pharmacogenetic Study

J. Benítez, A. González-Neira, G. Pita, 2011, PloS one.

Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma

J. Benítez, A. González-Neira, G. Pita, 2011, Nature Genetics.

Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients

J. Benítez, R. Milne, A. González-Neira, 2009, The Pharmacogenomics Journal.

Pharmacogenetic variants and response to neoadjuvant single-agent doxorubicin or docetaxel: a study in locally advanced breast cancer patients participating in the NCT00123929 phase 2 randomized trial

J. Benítez, A. González-Neira, G. Pita, 2018, Pharmacogenetics and genomics.

Vascular Endothelial Growth Factor Stimulates Organ-Specific Host Matrix Metalloproteinase-9 Expression and Ovarian Cancer Invasion

G. Taraboletti, R. Giavazzi, D. Belotti, 2008, Molecular Cancer Research.

Regulatory CDH4 Genetic Variants Associate With Risk to Develop Capecitabine‐Induced Hand‐Foot Syndrome

J. Benítez, R. Milne, A. González-Neira, 2020, Clinical pharmacology and therapeutics.